Synergy, additivism and antagonism in immunosuppression. A critical review.
about
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reductionEnhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in miceChloroquine inhibits T cell proliferation by interfering with IL-2 production and responsivenessSynergistic interaction between selective drugs in cell populations modelsSystems Pharmacology and Rational Polypharmacy: Nitric Oxide-Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General CaseAn Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines.Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.A pilot study to examine the effect of chronic treatment with immunosuppressive drugs on mucociliary clearance in a vagotomized murine modelNovobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.A proposed approach to study the toxicology of complex mixtures of petroleum products: the integrated use of QSAR, lumping analysis and PBPK/PD modeling.A nonlinear isobologram model with Box-Cox transformation to both sides for chemical mixturesDemonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitroSynergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitroSynergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study.Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158)Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation.Combination treatment of invasive fungal infections.Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models.L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B streptococci.Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism.Synergistic reaction of silver nitrate, silver nanoparticles, and methylene blue against bacteria.Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Recent advances of cocktail chemotherapy by combination drug delivery systems.Analysis of drug combinations: current methodological landscape.Assessment of non-linear combination effect terms for drug-drug interactions.The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanomaEnv-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsUse of pharmacodynamic indices to predict efficacy of combination therapy in vivo.Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling.Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions.Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.Drug interaction: focusing on response surface models.The combined use of antilymphocyte serum and cyclophosphamide to suppress renal allograft rejection in the rat.2-Deoxy-D-glucose Restore Glucocorticoid Sensitivity in Acute Lymphoblastic Leukemia via Modification of N-Linked Glycosylation in an Oxygen Tension-Independent Manner.Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes.
P2860
Q28196336-E08DE205-92DA-40CA-BA2C-42967165BCBCQ28366917-67EDA199-8273-468F-8C7C-94BE1282B584Q28367732-FB9CA588-DB3D-4103-8BB7-E2505BB3EC8AQ28543382-C1DC3C14-6D40-4646-B1F3-98BFD76AFDB3Q28550867-558B420F-E7ED-4759-A42A-E26EB5789CF7Q33580906-D61A0079-BDAA-4113-9CAE-5081D6495A19Q33908498-345F8810-AED1-437E-86D6-9F27DE9BDD12Q34052471-C51EE6F9-E2CC-41EA-880F-7F7BC7A48874Q34428705-1120131B-AEC2-48D4-987F-D975EF89F7BEQ34572663-2149C88A-C4AF-4281-897F-1E95E39CA6FBQ34640379-801D78EE-A2B3-4BF3-BC28-15794118F490Q34942592-8FE407DE-CD29-420E-B0D6-7255489FE48AQ35120560-4F4BAD7E-C2DF-4B88-B45B-F2503ACCFA6CQ35466926-F65493B2-A863-4F06-A3B1-60F3F20C43F4Q35563896-327C40F2-A5FC-4048-9AE4-D7B71C6BD3C4Q35594522-27D15ED0-B2AF-4F6A-884D-DC372FEC3947Q35995243-74D3A643-7795-4759-879E-5CC1FD7E7164Q36011378-C4579A4F-388C-4620-8D4F-DB032A84E040Q36012629-3EFBE910-3FC8-421E-9315-C58A3E6DF25CQ36018153-EFCFDCFB-F137-4D2A-B6FA-FB42343CF769Q36183063-A562950B-F245-4A86-9468-F64D183B5558Q36193870-54D2D3D3-82AF-4108-A2B6-4898D2924CC5Q36378398-D7301D9B-E6CB-4184-BD7C-DF0AB3C69D6DQ36557486-D0DB5853-B24F-4E80-B004-85AF829BB341Q36933169-C2F89840-61AD-45C7-A9F5-32F6FD900291Q37206908-43899E47-7AAF-4881-8BBD-E21F110A58F7Q38546567-A611742D-7208-476F-851B-BB540FE37D4FQ38957295-CA604E4D-0D65-43B1-94D0-4A863C4EF230Q38981033-329861EF-8C76-498B-8BE8-404721BE0751Q39454698-F05EEF8C-E1D0-4EDA-8B78-A8C92EA3B95CQ39471967-69C63A8C-7466-4823-8475-86FF804A39EDQ39478859-7759FCE6-01AD-4296-A89E-FF10E023AFB1Q39586182-C8E99D9C-547D-4271-89CB-F907C7664656Q39852169-5894FCA2-334B-48AF-A6DF-755C51040FF2Q39865219-1D4A55D2-86CF-4DCC-90F3-F6871E534912Q39981784-DE614DE9-DBD1-4477-9B76-11064248A797Q40907848-6CFE04F1-476A-4ABC-A0E5-55438E23CCD8Q41032191-3458BB3D-A838-4066-ACF3-284F5571A727Q41320019-1DE0E52E-5649-4630-8573-71A712246544Q41875185-D589DF2D-EF16-48DC-8C7E-ADFF290922E5
P2860
Synergy, additivism and antagonism in immunosuppression. A critical review.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Synergy, additivism and antagonism in immunosuppression. A critical review.
@en
Synergy, additivism and antagonism in immunosuppression. A critical review.
@nl
type
label
Synergy, additivism and antagonism in immunosuppression. A critical review.
@en
Synergy, additivism and antagonism in immunosuppression. A critical review.
@nl
prefLabel
Synergy, additivism and antagonism in immunosuppression. A critical review.
@en
Synergy, additivism and antagonism in immunosuppression. A critical review.
@nl
P1476
Synergy, additivism and antagonism in immunosuppression. A critical review.
@en
P2093
Berenbaum MC
P577
1977-04-01T00:00:00Z